ZERO Cancer

Incontinence Drug Toviaz Performs Well in Elderly Patients

Prostate.net

Dec 7, 2011

There’s reassuring news for those who are among the 33 million Americans with overactive bladder: the prescription drug Toviaz (fesoterodine) performed well in a new double-blind, placebo-controlled trial of 562 elderly men and women with overactive bladder. According to Pfizer Inc., which makes Toviaz, the drug was better than placebo in reducing the number of urinary incontinence episodes participants had each day.

The results of the 12-week trial are particularly important because it is the first study of an antimuscarinic agent (one that blocks the activity of the neurotransmitter acetylcholine) shown to be effective in treating older adults, for whom overactive bladder is especially troublesome and can be debilitating. Overactive bladder is a type of urinary incontinence that can be treated with a variety of medications, including Toviaz, as well as herbal and natural remedies, nerve stimulation, behavioral therapy, Kegel exercises, continence products, and surgery.

Powered by ARCOS | Design by Floyd & Partners

ZERO — The End of Prostate Cancer · 515 King St., · Suite 420 · Alexandria, VA 22314 · P: 202-463-9455 · F: 571-257-8559

BBB Accredited Charity Validate TRUSTe privacy certificationZERO does not endorse any course of treatment for men with prostate cancer or other conditions. Treatment decisions should be made by a patient and his health service provider. If you have problems with the site or need more information, please call us at 1.888.245.9455 or e-mail your comments. All names, logos and articles are the copyrights of the respective owners.

© 2011 All Rights Reserved. Contact Us | Privacy Policy